Navigation Links
BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
Date:8/5/2013

JERUSALEM, Aug. 5, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production.

(Logo: http://photos.prnewswire.com/prnh/20130730/630769)

The findings were published in the British Journal of Hematology, a leading journal in the field. The study, headed by Prof. Amnon Peled from the Goldyne Savad Institute of Gene Therapy - Hadassah University Hospital, assessed the effect of repeated doses of BL-8040 on healthy and chemotherapy-induced thrombocytopenic mice. The results show that repeated administration of BL-8040 significantly increased the number of megakaryocytes (cells that produce platelets) within the bone marrow; this was associated with increased production and increased levels of platelets in the blood circulation, in both the healthy and chemotherapy induced-thrombocytopenic mice. In addition, BL-8040 increased the number of hematopoietic progenitor cells within the bone marrow and in the blood. These cells are important for generating not only platelets but the whole gamut of red and white blood cells. In addition, BL-8040 significantly reduced the severity and duration of chemotherapy-induced thrombocytopenia and cytopenia.

"We are currently developing BL-8040 for acute myeloid leukemia (AML), and a Phase 2 clinical trial for this indication is underway at the MD Anderson Cancer Center in Houston and other leading centers in the U.S. and Israel," said Kinneret Savitsky, Ph.D., CEO of BioLineRx. "We h
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , a manufacturer of ergonomically designed laboratory equipment for ... Japan to sell and service the Hitachi ... will utilize its network of sales professionals throughout the ... offer assistance in application use, product benefits and features, options and ...
(Date:1/14/2014)... Jan. 14, 2014   Oligomerix, Inc. , a privately held ... Alzheimer,s disease (AD) and related neurodegenerative disorders, announced today ... Valhalla, NY as of January 15, 2014 ... New York Medical College. Oligomerix, which is ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014   Evidera ... healthcare industry, announced that the Center for Drug Evaluation ... released its first draft qualification guidance document for a ... of Exacerbations of Chronic Pulmonary Disease Tool [EXACT] for ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... Md., Feb. 25 Adlyfe, a private company developing ... today that it has signed an agreement with Wyeth ... designed to measure levels of beta amyloid in the ... specific beta amyloid targets for use in facilitating the ...
... Many soldiers who experienced mild head trauma or a ... to the United States with headaches, according to a study ... of Neurology,s 61st Annual Meeting in Seattle, April 25 to ... 978 U.S. Army soldiers returning from Iraq or Afghanistan in ...
Cached Medicine Technology:Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimer's Biomarker Assay 2For Iraq Veterans, Headaches Continue After Traumatic Brain Injury 2
(Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
(Date:4/17/2014)... international team led by researchers at UC Davis has ... a key role in cell division, also boosts the ... first time the complex has been shown to perform ... an excellent target to control cellular energy production, potentially ... published online today in the journal Developmental Cell ...
(Date:4/17/2014)... Meaningful long-term survival is possible for selected ... when treated with cytoreductive surgery with Hyperthermic IntraPeritoneal ... by physicians at Wake Forest Baptist Medical Center. ... single-center experience with cytoreductive surgery and HIPEC, said ... of 20 years, worth of patient data shows ...
(Date:4/17/2014)... after they suffer a cardiac arrest outside of a ... according to new research conducted at St. Michael,s Hospital. ... cardiac arrest get adrenaline, which has been the drug ... Steve Lin, an emergency physician and trauma team leader ... long-term survival rates of patients who suffer a cardiac ...
(Date:4/16/2014)... April 15, 2014 The Translational Genomics Research Institute ... annual Founders Dinner for their support of TGen,s research ... place March 28 in Scottsdale. , Catherine Ivy, Founder ... received TGen,s John S. McCain Leadership Award, named for ...
Breaking Medicine News(10 mins):Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... Specialty Health Care Distributor Appoints Longtime Cardinal Health Executive ... and DUBLIN, Ohio, June 8 Sarnova, the nation,s leading ... medical services and respiratory markets, announced today that it ... A former president with Cardinal Health, Inc., Mr. Struik, ...
... , COSTA MESA, Calif., June 8 Oxygen Biotherapeutics, Inc. ... signed a securities purchase agreement and commenced an offer to ... the company,s common stock that are issued in the transactions ... of 1933, as amended, and may not be offered or ...
... Schwade, M.D. executive director of the CyberKnife Center of Miami ( ... Ultimate Miami CEO,s by the South Florida Business Journal. , , ... ten winners chosen as successful Miami businessmen who are among the upper ... CEO award winners include the following people: , , ...
... family-building benefits for its employees , , WOONSOCKET, R.I., ... is proud to announce it has been named one of ... for offering superior family-building benefits, such as health insurance coverage ... paid and unpaid leave for birth and adoptions. CVS ...
... June 8 On June 7th, Little Hearts, Inc. held ... One of the support services they offer is their "Picture ... kids ranging in age from infant to 50 of all ... (52), PA, TGA, TOF and Tricuspid Atresia. "HOPE" is shared ...
... to sleep deficit, researchers warn , MONDAY, June 8 (HealthDay ... fatigue probably signaled it was time to go to sleep. ... Housewives are more influential in determining bedtimes -- and ... a new study says. , In the study, researchers looked ...
Cached Medicine News:Health News:Sarnova Names Hank Struik Chief Executive Officer 2Health News:Sarnova Names Hank Struik Chief Executive Officer 3Health News:Oxygen Biotherapeutics, Inc. Announces Private Placement Financing Agreement and Offer to Acquire Warrants 2Health News:Oxygen Biotherapeutics, Inc. Announces Private Placement Financing Agreement and Offer to Acquire Warrants 3Health News:CVS Caremark Ranks Among 50 Best Fertility- and Adoption-Friendly Workplaces in America 2Health News:CVS Caremark Ranks Among 50 Best Fertility- and Adoption-Friendly Workplaces in America 3Health News:Members of National CHD Organization Unite for Little Hearts' Celebration and Assemble for 'Picture of Hope' 2Health News:Glowing TV Screens Keeping Americans Up at Night 2
ACTH EIA Hypertension / Cardiac Evaluation, Cardiovascular 021-SDX018...
... a solid phase two-site enzyme immunoassay. ... technique in which two monoclonal antibodies are ... human insulin molecule. During incubation, insulin ... antibodies and anti-insulin antibodies bound to the ...
... hormone responsible for the control of glucose metabolism. ... the islets of Langerhans as the precursor, proinsulin, ... Both are secreted in equimolar amounts into ... is comprised of two polypeptide chains, the A-chain ...
... an integral part of the enzymatic cascade ... as well as the degradation of Bradykinin. ... is primarily located in endothelial cells. ACE ... for sarcoidosis and myocardial infarction but is ...
Medicine Products: